Roivant Sciences Ltd. (NASDAQ:ROIV) Given Average Rating of “Moderate Buy” by Brokerages

Roivant Sciences Ltd. (NASDAQ:ROIV) has earned a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $17.93.

Several equities research analysts recently commented on ROIV shares. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research report on Wednesday, November 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. Finally, Bank of America boosted their price target on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research report on Wednesday, September 11th.

Insider Transactions at Roivant Sciences

In other news, Director Financial Lp Qvt sold 876,000 shares of the business’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $11.82, for a total transaction of $10,354,320.00. Following the transaction, the director now directly owns 22,179,358 shares in the company, valued at $262,160,011.56. The trade was a 3.80 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Eric Venker sold 100,000 shares of the business’s stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $11.65, for a total transaction of $1,165,000.00. Following the transaction, the chief operating officer now owns 617,470 shares in the company, valued at $7,193,525.50. This represents a 13.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 3,677,309 shares of company stock worth $43,283,184 in the last ninety days. Insiders own 7.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC grew its stake in Roivant Sciences by 5.6% in the 3rd quarter. FMR LLC now owns 49,145,056 shares of the company’s stock valued at $567,134,000 after buying an additional 2,593,910 shares during the last quarter. Rubric Capital Management LP grew its stake in Roivant Sciences by 15.0% in the 2nd quarter. Rubric Capital Management LP now owns 23,000,000 shares of the company’s stock valued at $243,110,000 after buying an additional 3,000,000 shares during the last quarter. State Street Corp grew its stake in Roivant Sciences by 6.1% in the 3rd quarter. State Street Corp now owns 19,561,249 shares of the company’s stock valued at $225,737,000 after buying an additional 1,118,561 shares during the last quarter. Geode Capital Management LLC grew its stake in Roivant Sciences by 23.2% in the 3rd quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company’s stock valued at $89,400,000 after buying an additional 1,460,205 shares during the last quarter. Finally, DME Capital Management LP grew its stake in Roivant Sciences by 14.8% in the 2nd quarter. DME Capital Management LP now owns 4,810,960 shares of the company’s stock valued at $50,852,000 after buying an additional 620,470 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Trading Down 0.3 %

ROIV opened at $11.84 on Monday. The stock has a market capitalization of $8.62 billion, a P/E ratio of 2.10 and a beta of 1.25. Roivant Sciences has a 12 month low of $9.69 and a 12 month high of $13.06. The firm’s fifty day simple moving average is $11.88 and its 200 day simple moving average is $11.45.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.